Back to top

Image: Bigstock

Is This the Right Time to Hold Resmed Stock in Your Portfolio?

Read MoreHide Full Article

Key Takeaways

  • Resmed's AirSense 11 rollout and connected care expansion are driving growth in global sleep device sales.
  • RMD's Rest of World sleep device sales rose 13%, while masks and other revenues increased 11% in Q1 FY27.
  • Resmed faces competitive and cost pressures, with non-GAAP operating margin contracting 30 bps to 35.8%.

Resmed (RMD - Free Report) benefits from the global supply of AirSense10 and AirSense11 cloud-connected platforms. The company’s continuous efforts to expand its footprint across international markets look encouraging. Yet, headwinds from macroeconomic pressures and intense competition may present operational risks for Resmed.

Over the past year, this Zacks Rank #3 (Hold) stock has lost 2.9% compared with the industry’s 19.5% decline. The S&P 500 composite has grown 11.3% over the same period.

The renowned medical device company has a market capitalization of $34.12 billion. RMD has an earnings yield of 5% compared with the industry’s 2.9%. RMD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 4.4%.

Let’s delve deeper.

Upsides for RMD Stock

Connected Device Expansion: Resmed’s device franchise is benefiting from the continued global rollout of AirSense 11 and broader use of connected care tools. In the first quarter of fiscal 2027, Americas sleep device revenues increased 6% to $436 million, while Rest of World sleep device revenues rose 13% to $280 million on a core constant-currency basis. 

Resmed continued expanding AirCurve 11 ST and ST-A in the United States. Its FDA-cleared Smart Comfort technology demonstrated a 4.3% increase in 30-day compliance compared with default settings. A broader connected installed base can support future mask and accessory resupply while linking more providers and patients through the company’s digital ecosystem.

Increased Focus on International Markets: Resmed continues to expand in international sleep-health markets where diagnosis and treatment remain underpenetrated. The strategy combines local market development, connected device launches, new masks and consumer education with a global manufacturing and distribution footprint. In the first quarter of fiscal 2027, Rest of World sleep device revenues increased 13% on a core constant-currency basis, while Masks and other revenues advanced 11%. 

Resmed continues to extend AirSense 11 and AirCurve 11 availability across international markets. Its partnership with Oura generated approximately 28,000 visits to Resmed.com, with roughly 72% of assessment participants previously undiagnosed. Broader connected platforms and patient education can expand therapy initiation and recurring mask demand across international markets.

 

Zacks Investment Research
Image Source: Zacks Investment Research

Concerns for RMD

Competitive Landscape: The market for sleep-disordered breathing products remains highly competitive on price, product features, reliability and supply performance. Large providers and payers can gain purchasing leverage as healthcare markets consolidate, making account retention costlier. Some competitors are also affiliated with customers, creating additional channel risk in selected markets. Continued differentiation in mask comfort, device connectivity and digital services remains necessary in defending pricing and market share. Failure to maintain those advantages could weaken recurring resupply economics and reduce profitability over time.

Macroeconomic and Cost Sensitivity: Resmed remains exposed to macroeconomic conditions, geopolitical instability, tariffs and trade actions that can affect demand and raise component, freight and labor costs. Currency movements can also influence reported results.

In the first quarter of fiscal 2027, non-GAAP operating margin contracted 30 basis points to 35.8%. Research and development expenses increased 16% on a non-GAAP basis, while non-GAAP selling, general and administrative expenses rose 6%. Management expects continued inflationary effects and only a slight increase in non-GAAP operating margin for fiscal 2027. Productivity initiatives and pricing actions are intended to offset higher costs, but sustained investment requirements could limit earnings leverage.

RMD Stock’s Estimate Trend

The Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has moved south 0.9% to $12.14 in the past 30 days. 

The Zacks Consensus Estimate for fiscal 2027 revenues is pegged at $5.82 billion, up 3% from the year-ago reported figure.

Key Picks

Some better-ranked stocks in the broader medical space are Bausch + Lomb Corp. (BLCO - Free Report) , Insulet (PODD - Free Report) and IDEXX Laboratories (IDXX - Free Report) . 

Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2%. Shares of the company have rallied 43.3% compared with the industry’s 9.9% gain over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%. 

BLCO sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4% compared with the industry’s 9.3%. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 59.6% compared with the industry’s 20.7% decline over the past year.

IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have risen 0.2% compared with the industry’s 2.4% growth over the past year.

Published in